Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Short Interest Update

Key Points

• Short interest fell 24.7% to 48,120 shares as of April 15, representing 0.6% of shares short and a short-interest ratio of 1.9 days based on average daily volume.
• Director Yusheng Han bought 314,870 shares at an average $17.36 on March 31, raising his stake to 17,672,676 shares as insiders now own about 30.3% of the company.
• Burning Rock trades with a market cap of $179.2M, reported a (‑$0.21) EPS and negative margins last quarter, and carries a consensus analyst rating of "Sell".

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR - Get Free Report) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 48,120 shares, a decline of 24.7% from the March 31st total of 63,946 shares. Currently, 0.6% of the shares of the company are short sold. Based on an average daily volume of 25,429 shares, the short-interest ratio is currently 1.9 days.

Insider Activity at Burning Rock Biotech

In related news, Director Yusheng Han bought 314,870 shares of the company's stock in a transaction that occurred on Tuesday, March 31st. The shares were acquired at an average price of $17.36 per share, with a total value of $5,466,143.20. Following the completion of the transaction, the director owned 17,672,676 shares of the company's stock, valued at $306,797,655.36. The trade was a 1.81% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 30.30% of the company's stock.

Institutional Investors Weigh In On Burning Rock Biotech

Several institutional investors and hedge funds have recently bought and sold shares of BNR. China Universal Asset Management Co. Ltd. bought a new stake in Burning Rock Biotech in the 3rd quarter valued at $26,000. Prospera Financial Services Inc bought a new stake in Burning Rock Biotech in the 3rd quarter valued at $214,000. Marshall Wace LLP bought a new stake in Burning Rock Biotech in the 4th quarter valued at $220,000. Finally, Crcm LP increased its holdings in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company's stock valued at $1,917,000 after buying an additional 26,809 shares during the period. Institutional investors own 30.03% of the company's stock.

Burning Rock Biotech Price Performance

NASDAQ:BNR opened at $16.65 on Wednesday. The stock has a market cap of $179.15 million, a P/E ratio of -21.08 and a beta of 1.59. Burning Rock Biotech has a one year low of $2.18 and a one year high of $41.72. The company has a fifty day moving average price of $20.63 and a 200 day moving average price of $20.80.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($0.21) EPS for the quarter. The company had revenue of $18.05 million for the quarter. Burning Rock Biotech had a negative net margin of 10.27% and a negative return on equity of 9.98%.

Analysts Set New Price Targets

Several research firms recently commented on BNR. Weiss Ratings reiterated a "sell (d-)" rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Burning Rock Biotech from a "hold" rating to a "buy" rating in a research note on Saturday, January 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Burning Rock Biotech currently has a consensus rating of "Sell".

Burning Rock Biotech Company Profile

Burning Rock Biotech NASDAQ: BNR is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company's core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.